Literature DB >> 2728813

A weight-related intravenous dexamethasone suppression test distinguishes obese controls from patients with Cushing's syndrome.

A B Atkinson1, E J McAteer, D R Hadden, L Kennedy, B Sheridan, A I Traub.   

Abstract

To establish a rapid test for Cushing's syndrome we measured serum cortisol during and following iv dexamethasone infusion (5 micrograms.kg-1.h-1 for 5 h from 10.00 h) in simple obesity (N = 19) and in Cushing's syndrome (N = 12). We had first established that 5 micrograms.kg-1.h-1 was the lowest dose which consistently lowered serum cortisol in simple obesity. In obesity, serum cortisols ranged from undetectable (less than 30) to 48 nmol/l at 17.00, less than 30 to 37 at 19.00 and less than 30 to 38 at 08.00 h the following day. Serum cortisol at these three times did not show any overlap between simple obesity and Cushing's syndrome. Having established these findings we proceeded to study a group of patients with polycystic ovarian disease. These patients behaved differently. Their values at 17.00 and 19.00 h did not overlap those of Cushing's syndrome. However, at 08.00 h, 5 of the 7 had values within the range seen in Cushing's syndrome with a mean of 290 +/- 99 nmol/l. In conclusion, 17.00 and 19.00 h serum cortisol levels distinguish between Cushing's syndrome and both simple obesity and polycystic ovarian disease. However, in the latter, cortisol suppression is less prolonged than in simple obesity. This finding may be important for our understanding of the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2728813     DOI: 10.1530/acta.0.1200753

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  2 in total

1.  Screening for Cushing's syndrome in obese women with and without polycystic ovary syndrome.

Authors:  P Putignano; M Bertolini; M Losa; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

Review 2.  The investigation of Cushing syndrome: essentials in optimizing appropriate diagnosis and management.

Authors:  Agata Juszczak; Ashley Grossman
Journal:  Ann Saudi Med       Date:  2012 Sep-Oct       Impact factor: 1.526

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.